News | February 17, 2015

Heart Problems Among Potential Issues for Cancer Survivors

Experts recommend echocardiograms to help patients stay heart-healthy

cancer survivors, cardiovascular ultrasound, echocardiograms

February 17, 2015 — Certain types of chemotherapy are associated with heart issues known as cancer therapeutics-related cardiac dysfunction. However, symptoms don’t appear until the issue is already advanced and potentially deadly. Experts at Baylor College of Medicine say early screening and monitoring using echocardiograms could be the key to helping cancer survivors stay heart-healthy and get their life back.

These recommendations are part of an expert consensus statement from a consortium of doctors and researchers published recently in the Journal of American Society of Echocardiography. The report is from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.  

“Oncologists do an excellent job of finding the right treatments for each type of cancer,” said Juan Carlos Plana, M.D., associate professor of medicine and director of the cardio-oncology center at Baylor. “But cancer treatments are harsh and can affect the heart in different ways for each person. That is why cardiologists should be part of the care team for at-risk cancer patients.”

What doctors should be monitoring for, Plana said, is left ventricular ejection fraction (LVEF), the measurement of how much blood is being pumped out of the main pumping chamber of the heart. A decrease in the pressure of each squeeze during or after cancer treatment means that cancer therapeutics-related cardiac dysfunction is more likely to occur down the line.  

“We reviewed past studies and patient cases and found that a drop by 15 percent of strength over the course of treatment, with measurements starting before treatment and continuing after treatment, is an indication that there will be heart problems down the line,” said Plana, who also is lead author on the published recommendations. “That is why it is important to get a baseline test before treatment starts, and continue being tested periodically depending on your doctor’s recommendation. Early detection means intervention can begin before it is too late.”

Plana added that additional monitoring of global longitudinal strain, which looks at the function of myocardial fibers, also has been shown to help predict future cancer therapeutics-related cardiac dysfunction. Myocardial fibers are sensitive to the restriction of blood flow and wall stress and are a good indication that blood flow through the heart is not functioning normally.

“These indications of heart trouble down the line don’t necessarily have noticeable symptoms. In fact, the heart can adapt and compensate for lack of function to a certain degree, but you are basically living on the edge,” Plana said.

For more information: www.onlinejase.com

Related Content

FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
360 Photos | Ultrasound Imaging | July 11, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
360 Photos | Ultrasound Imaging | July 09, 2019
A view of a mitral valve on a GE Healthcare Vivid E95 ...
360 Photos | Ultrasound Imaging | July 08, 2019
This is a 360 degree view of a live cardiac echo demonstration for the Siemens Healthineers Acuson SC2000...
3D Auto RV application image courtesy of Philips Healthcare

3D Auto RV application image courtesy of Philips Healthcare

Technology | Cardiovascular Ultrasound | July 02, 2019
Philips recently announced new advanced automation capabilities on its Epiq CVx and Epiq CVxi cardiac ultrasound...
Konica Minolta Healthcare Partners With DiA Imaging Analysis for AI-based Cardiac Ultrasound Analysis
News | Cardiovascular Ultrasound | July 02, 2019
DiA Imaging Analysis has partnered with Konica Minolta Healthcare Americas Inc. to expand analysis capabilities of...
The Acuson Sequoia with Deep Abdominal Transducer (DAX) scanning a 600 pound patient.

The Acuson Sequoia with Deep Abdominal Transducer (DAX) scanning a 600 pound patient.

Sponsored Content | Case Study | Ultrasound Imaging | July 01, 2019
“With our present technology, we often struggle with large patients,” said Richard G.
FDA Issues Final Guidance on Marketing Clearance of Diagnostic Ultrasound Systems and Transducers
News | Ultrasound Imaging | June 27, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance: Marketing Clearance of Diagnostic Ultrasound...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...